STM | Nano Publications

2018 – ASTRO 2018 – Phase III NBTXR3 in Soft Tissue Sarcoma

Abstracts, Donnée clinique de NBTXR3, STM

A subset of soft tissue sarcoma (STS) patients achieve significant therapeutic benefit from preoperative radiotherapy (RT). Yet, this treatment paradigm may be associated with limited efficacy and increased toxicity, highlighting the necessity of novel multimodal therapies aimed at local control with few adverse events (AEs). NBTXR3 is a first-in-class Hafnium-Oxide nanoparticle. […]

Continuer la lecture…

2017 – Abstract – 13th Journées cancéropole GSO – HfO2 nanoparticles in solid tumors

Abstracts, Donnée clinique de NBTXR3, Foie, Rectum, STM, Tête & Cou

The enclosed abstract was presented at the 13th Journées cancéropole Grand Sud-Ouest at Poitiers. The abstract Hafnium oxide nanoparticles as an emergent promising treatment for solid tumors describes how hafnium oxide nanoparticles were designed at the nanoscale in the form of crystalline 50nm-particles to efficiently absorb ionizing radiation and increase the radiation dose deposited – “hot spots” of energy deposit – from within the tumor cells for efficient cell killing. […]

Continuer la lecture…

2018 – ESTRO – Hafnium Oxide Nanoparticles and Radiotherapy: A Promising New Treatment Strategy

Abstracts, Donnée clinique de NBTXR3, Foie, Rectum, STM, Tête & Cou

With recent advances in radiation delivery techniques, an increasing number of cancer patients undergo radiotherapy. However, due to the non-targeted nature of radiotherapy, doses are limited by potential toxicity to surrounding normal tissue. Thus, a major challenge remains to develop new strategies to improve the tumor selectivity of radiation therapy. […]

Continuer la lecture…

2017 – Abstract – CTOS – NBTXR3 induces antitumoral immune response in human STS

Abstracts, Donnée clinique de NBTXR3, STM

The enclosed abstract was presented at the “2017 Connective Tissue Oncology Society Annual Meeting (CTOS), Maui, Hawaii”. The abstract “NBTXR3 Treatment Induces Antitumoral Immune Response in Human Soft Tissue Sarcoma” describes how NBTXR3 activated by RT triggers an enhanced adaptive immune response and contributes to transform “cold” tumor into “hot” tumor.

Continuer la lecture…

2017 – Abstract SITC Conference Maryland – Clinical

Abstracts, Donnée clinique de NBTXR3, STM

Soft tissue sarcoma (STS) is a large and heterogeneous group of malignant mesenchymal neoplasms characterized by a strong tendency toward local recurrence and metastatic spreading. Consistently, the immune microenvironment in sarcomas is highly variable. A new class of material with high electron density, hafnium oxide, was designed at the nanoscale to efficiently absorb ionizing radiation […]

Continuer la lecture…

2017 – Specific adaptive immune pattern induced by NBTXR3 exposed to radiation therapy in soft tissue sarcoma (STS) patients

Abstracts, Donnée clinique de NBTXR3, STM

NBTXR3 are functionalized hafnium oxide nanoparticles, undergoing seven clinical trials for enhancing radiation therapy (RT). The high electron density of the nanoparticles, when exposed to radiotherapy (NBTXR3 + RT), allow absorption/deposition of a high radiation dose within the cancer cells to physically kill the cells, and possibly improve outcome. Besides, NBTXR3 + RT has shown subsequent ability to enhance immunogenic cell death and immune response in preclinics. We hypothesized that NBTXR3 + RT could trigger an enhanced immune response when compared to RT in patients with STS.

Continuer la lecture…

2014 – ASCO Abstract – Preliminary Data NBTXR3 Soft Tissue Sarcoma – Bonvalot et al.

Abstracts, Donnée clinique de NBTXR3, STM

Functionalized hafnium oxide nanoparticles (NBTXR3) have been developed as selective radioenhancers, which may represent a breakthrough approach for the local treatment of solid tumors. This is a unique approach where crystalline nanomaterials with high electron density when exposed to radiotherapy, can allow penetrate into the cell and make feasible the absorption/deposition of a high energy dose within the tumor cell. A phase I/II trial was implemented in patients with locally advanced STS.

Continuer la lecture…